Download Files:
Seralutinib
$140 – $1,050
Products Details
Product Description
– Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension[1][2].
Web ID
– HY-109190
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C27H27N5O3
References
– [1]Anna Galkin, et al. Abstract 11102: Gb002, A Novel Inhaled Pdgfr Kinase Inhibitor, Demonstrates Efficacy in the Su5416 Hypoxia Rat Model of Pulmonary Arterial Hypertension (pah). Circulation. 2019;140:A11102.|[2]Anna Galkin, et al. Pharmacologic Characterization of GB002, a Novel Inhaled PDGFR Kinase Inhibitor in Development for Pulmonary Arterial Hypertension (PAH).|[3]Robert P. Frantz1, et.al. Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 (Seralutinib) for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
CAS Number
– 1619931-27-9
Molecular Weight
– 469.53
Compound Purity
– 99.77
SMILES
– O=C(C1=CC(C)=CN=C1)NC2=CC=CC([C@@H](NC3=NC(C4=CC=C(OC)C(OC)=C4)=CN=C3)C)=C2
Clinical Information
– Phase 3
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 200 mg/mL (ultrasonic)
Target
– c-Fms;c-Kit;PDGFR
Isoform
– PDGFRα;PDGFRβ
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
